(PRESS RELEASE) BEDFORD, MA - Ocular Therapeutix Inc. (NASDAQ: OCUL) announced the closing of its underwritten public offering of 7,475,000 shares of its common stock at a public offering price of $5 per share.

The shares of common stock issued and sold in the offering at the closing include 975,000 shares issued upon the exercise in full by the underwriter of its option to purchase additional shares at the public offering price, less underwriting discounts and commissions. The offering was made pursuant to a shelf registration statement that was previously filed with and declared effective by the Securities and Exchange Commission. All of the shares in the offering were sold by Ocular.

The aggregate net proceeds before expenses to Ocular from the offering are approximately $35.1 million, after deducting underwriting discounts and commissions.

Piper Jaffray & Co. acted as sole manager and underwriter for the offering.

Ocular intends to use the net proceeds from the offering, together with its existing cash and cash equivalents, to fund the planned resubmission of its new drug application for DEXTENZA, to fund the clinical development of OTX-TP, OTX-TIC and OTX-TKI, to fund additional preclinical and regulatory activities for its other product candidates, including through its collaboration with Regeneron, and for working capital and other general corporate purposes and pursuit of its other research and development efforts.

The prospectus supplement and the accompanying prospectus for the offering and the other documents the Company has filed with the SEC, which are incorporated by reference in the prospectus supplement and the accompanying prospectus for the offering, provide more complete information about the Company and the offering. An electronic copy of the prospectus supplement and the accompanying prospectus for the offering are available on the website of the SEC at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained by contacting Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone: (800) 747-3924, or by email: This email address is being protected from spambots. You need JavaScript enabled to view it..

 

This story is tagged under: